Last reviewed · How we verify
DMB-3115
DMB-3115 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.
DMB-3115 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain. Used for Schizophrenia.
At a glance
| Generic name | DMB-3115 |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | PDE10A inhibitor |
| Target | PDE10A |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | Phase 3 |
Mechanism of action
PDE10A is predominantly expressed in medium spiny neurons of the striatum and is involved in dopamine and cAMP signaling. By inhibiting PDE10A, DMB-3115 enhances cAMP-mediated signaling, which may modulate dopaminergic and glutamatergic neurotransmission. This mechanism is hypothesized to provide therapeutic benefit in movement and psychiatric disorders.
Approved indications
- Schizophrenia
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DMB-3115 CI brief — competitive landscape report
- DMB-3115 updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI